Literature DB >> 15120747

Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus.

Andrey M Mazarati1, Roger Baldwin, Henrik Klitgaard, Alain Matagne, Claude G Wasterlain.   

Abstract

Status epilepticus (SE) is a neurological emergency, with high mortality and high morbidity among survivors, and novel therapeutic agents are needed to improve this picture. We examined the effects of the antiepileptic drug levetiracetam (LEV) in an experimental model of self-sustaining status epilepticus (SSSE), induced in rats by electrical stimulation of the perforant path. LEV's unique spectrum of anticonvulsant activity, very high therapeutic index, and neuroprotective properties, make it a potentially interesting agent in the treatment of SE. Pretreatment with LEV intravenously reduced (30 mg/kg) or prevented (50-1000 mg/kg) the development of self-sustaining seizures. Treatment during the maintenance phase of SSSE diminished (at 200 mg/kg) or aborted seizures (in doses of 500 or 1000 mg/kg). Addition of LEV significantly enhanced the anticonvulsant effects of diazepam (DZP), even when both drugs where given in doses far below their therapeutic level. We conclude that LEV deserves further evaluation in the treatment of status epilepticus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120747     DOI: 10.1016/j.eplepsyres.2004.02.002

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  22 in total

1.  The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus.

Authors:  Claude G Wasterlain; Thomas Stöhr; Alain Matagne
Journal:  Epilepsy Res       Date:  2011-01-28       Impact factor: 3.045

2.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 4.  Neurologic complications of cardiac surgery: current concepts and recent advances.

Authors:  David J Bronster
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

Review 5.  Synergistic neuroprotective therapies with hypothermia.

Authors:  Maria Roberta Cilio; Donna M Ferriero
Journal:  Semin Fetal Neonatal Med       Date:  2010-03-07       Impact factor: 3.926

Review 6.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

7.  Intravenous levetiracetam in the rat pilocarpine-induced status epilepticus model: behavioral, physiological and histological studies.

Authors:  Yi Zheng; Jon Moussally; Sydney S Cash; Havisha B Karnam; Andrew J Cole
Journal:  Neuropharmacology       Date:  2009-12-21       Impact factor: 5.250

8.  Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats.

Authors:  Mustafa Komur; Cetin Okuyaz; Yalcin Celik; Bora Resitoglu; Ayse Polat; Senay Balci; Lulufer Tamer; Semra Erdogan; Huseyin Beydagi
Journal:  Childs Nerv Syst       Date:  2014-02-14       Impact factor: 1.475

Review 9.  Clinical management of seizures in newborns : diagnosis and treatment.

Authors:  Linda G M van Rooij; Marcel P H van den Broek; Carin M A Rademaker; Linda S de Vries
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

10.  Sequential intrarectal diazepam and intravenous levetiracetam in treating acute repetitive and prolonged seizures.

Authors:  Pradeep N Modur; Warren E Milteer; Song Zhang
Journal:  Epilepsia       Date:  2009-10-20       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.